IRCT20210214050350N1 IRCT 2021-02-22 Iran University of Medical Sciences Comparing the effectiveness of Kaletra/Hydroxychloroquine and Atazanavir/Dolutegravir/Hydroxychloroquine treatment regiments in COVID-19 treatment Comparing the effectiveness of Lopinavir/Ritonavir/Hydroxychloroquine and Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine treatment regiments in moderate to severe COVID-19 patients 2021-02-14 anticipated 60 Complete https://irct.ir/trial/54295 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 3 COVID-19. Intervention 1: Intervention group: This group will receive Atazanavir (300 mg)\ Ritonavir (100 mg) twice a day - Dolutegravir (500 mg) once a day and Hydroxychloroquine (400 mg BD for the first day and 200 mg BD afterwards) tablets for 10 days and during this time their clinical and laboratory parameters will be monitored. Intervention 2: Control group: This group will receive Lopinavir (400 mg)\ Ritonavir (100 mg) twice a day and Hydroxychloroquine (400 mg BD for the first day and 200 mg BD afterwards) tablets for 10 days and during this time their clinical and laboratory parameters will be monitored. No - There is not a plan to make this available Justification or reason for not sharing IPD is Study data will only be provided to requests that were processed through the appropriate university channels